Nephroprotection by SGLT2 Inhibition: Back to the Future?

Journal of Clinical Medicine
Luca De NicolaRoberto Minutolo

Abstract

The introduction of sodium/glucose cotransporter 2 inhibitors (SGLT2i) has opened new perspectives for the management of diabetic population at risk of or with chronic kidney disease (CKD). More important, recent, large real-world studies have repositioned the nephroprotective efficacy of SGLT2i emerged from randomized trials within the frame of effectiveness. Furthermore, the salutary effects of these agents may extend to the nondiabetic population according to the positive results of current studies. Nevertheless, the clear benefits of these agents on the prevention of organ damage contrast with their unexpected, limited use in clinical practice. One potential barrier is the acute decline in glomerular filtration rate (GFR) commonly observed at the beginning of treatment. This phenomenon is reminiscent of the early response to the traditional nephroprotective interventions, namely blood pressure lowering, dietary protein and salt restriction and the inhibition of the renin-angiotensin system. Under this perspective, the "check-mark" sign observed in the GFR trajectory over the first weeks of SGT2i therapy should renew interest on the very basic goal of CKD treatment, i.e., alleviate hyperfiltration in viable nephrons in order...Continue Reading

References

Feb 8, 1992·BMJ : British Medical Journal·S BjörckM Aurell
Oct 19, 1999·The Journal of Clinical Investigation·J Schnermann, J P Briggs
Aug 6, 2004·The New England Journal of Medicine·David N JuurlinkDonald A Redelmeier
Oct 25, 2011·The American Journal of Medicine·Neil A Smart, Thomas T Titus
Jan 7, 2014·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Allon N FriedmanSharon Moe
Mar 29, 2014·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Luca De NicolaRoberto Minutolo
Feb 1, 2015·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Gary C W Chan, Sydney C W Tang
Nov 21, 2015·Journal of Nephrology·Mario PacilioLuca De Nicola
Jun 15, 2016·The New England Journal of Medicine·Christoph WannerUNKNOWN EMPA-REG OUTCOME Investigators
Feb 2, 2017·Journal of the American Society of Nephrology : JASN·Lennart TonneijckJaap A Joles
Jun 24, 2017·Journal of the American Society of Nephrology : JASN·Alfred K CheungUNKNOWN SPRINT Research Group
Mar 16, 2018·Journal of the American College of Cardiology·Mikhail KosiborodUNKNOWN CVD-REAL Investigators and Study Group
Apr 17, 2018·Kidney International·Katharina BrückUNKNOWN European CKD Burden Consortium
May 8, 2018·Kidney International·Hiddo J L HeerspinkDavid Z I Cherney
Jun 2, 2018·Journal of the American College of Cardiology·Matthew A CavenderUNKNOWN CVD-REAL Investigators and Study Group
Jun 26, 2018·The Lancet. Diabetes & Endocrinology·Vlado PerkovicBruce Neal
Sep 13, 2018·Diabetes, Obesity & Metabolism·Chintan V DaveElisabetta Patorno
Dec 13, 2018·American Journal of Physiology. Renal Physiology·Markus PirklbauerHerbert Schramek
Dec 19, 2018·Diabetes Care·UNKNOWN American Diabetes Association
Jan 24, 2019·Journal of Nephrology·Roberto MinutoloUNKNOWN Collaborative Study Group on the Conservative Treatment of CKD of the Italian Society of Nephrology
Feb 13, 2019·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Pantelis SarafidisMads Hornum
Mar 15, 2019·Journal of the American Society of Nephrology : JASN·Jie ZhangRuisheng Liu
Apr 17, 2019·The New England Journal of Medicine·Vlado PerkovicUNKNOWN CREDENCE Trial Investigators
Sep 10, 2019·Diabetes, Obesity & Metabolism·Dario GiuglianoKatherine Esposito
Sep 10, 2019·European Heart Journal·Francesco CosentinoUNKNOWN ESC Scientific Document Group
Oct 9, 2019·Clinical Journal of the American Society of Nephrology : CJASN·Alan S KligerUNKNOWN Diabetic Kidney Disease Task Force of the American Society of Nephrology
Oct 22, 2019·Endocrine Reviews·Yuliya LytvynDavid Z I Cherney
Dec 18, 2019·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·James B WetmoreDavid T Gilbertson

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT03036150
NCT03594110

Software Mentioned

SPRINT
CVD
CANVAS
CREDENCE
REAL
EMPAREG
CKD

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.